Medherize Platform Validates Clinical and Operational Gains in Breast Oncology
Event summary
- Independent evaluation of Medherize platform at CHU de Québec shows 97% patient adoption and 93% therapeutic adherence among 243 breast cancer patients.
- Platform reduced treatment interruptions to 17% (vs. expected 50%) and decreased pharmacist workload by 52%.
- Clinical team recommends making Medherize a permanent tool for monitoring CDK4/6 inhibitor patients.
- KDA Group plans to expand Medherize to other therapeutic areas to address Quebec's aging population and healthcare labor shortages.
The big picture
KDA Group's Medherize platform demonstrates significant clinical and operational benefits in breast oncology, addressing critical challenges in patient adherence and healthcare workforce efficiency. The results come as prescriptions for CDK4/6 inhibitors at CHU de Québec doubled from 2023 to 2025, highlighting the growing demand for digital solutions in oncology care. The platform's success could position KDA as a key player in healthcare technology, particularly in regions facing demographic and labor pressures.
What we're watching
- Expansion Strategy
- Whether KDA can successfully extend Medherize to other therapeutic areas beyond breast oncology.
- Market Adoption
- The pace at which other healthcare institutions in Quebec and beyond adopt the Medherize platform.
- Regulatory Compliance
- How KDA navigates data protection regulations like Law 25 while expanding the platform's use.
Related topics